Cargando…
Future of Management of Multiple Sclerosis in the Middle East: A Consensus View from Specialists in Ten Countries
The prevalence of multiple sclerosis (MS) is now considered to be medium-to-high in the Middle East and is rising, particularly among women. While the characteristics of the disease and the response of patients to disease-modifying therapies are generally comparable between the Middle East and other...
Autores principales: | Aljumah, Mohammed, Alroughani, Raed, Alsharoqi, I., Bohlega, Saeed A., Dahdaleh, Maurice, Deleu, Dirk, Esmat, Khaled, Khalifa, Ahmad, Sahraian, Mohammad A., Szólics, Miklós, AlTahan, Abdulrahman, Yamout, Bassem I., Rieckmann, Peter, Daif, Abdulkader |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877627/ https://www.ncbi.nlm.nih.gov/pubmed/24455267 http://dx.doi.org/10.1155/2013/952321 |
Ejemplares similares
-
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks
por: Alroughani, Raed, et al.
Publicado: (2016) -
Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring
por: Alroughani, Raed A, et al.
Publicado: (2014) -
MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis
por: Yamout, Bassem I, et al.
Publicado: (2021) -
Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review
por: AlSharoqi, Isa Ahmed, et al.
Publicado: (2020) -
The use of alemtuzumab in patients with relapsing-remitting multiple
sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)